News

Elderly people at increased risk of pulmonary hypertension (PH) are increasingly also being diagnosed with pulmonary arterial hypertension (PAH). Diagnosis and management in this group can be quite challenging, and a report from Geneva University Hospitals suggested that all elderly patients with suspected PAH should be referred to an expert center for…

To mark World PH Day on May 5, the Pulmonary Hypertension Association (PHA) will join with 80 other groups worldwide in celebrating the progress made in their common fight against pulmonary hypertension, an often-misdiagnosed and life-threatening lung disease. “In 25 years, here in the U.S., we’ve gone from zero to 14…

The Pulmonary Hypertension Association (PHA) announced the launch of “PH Care for All,” an initiative to address disparities in the treatment of pulmonary hypertension (PH) among minorities and low-income patients in the United States, and led by 26 highly regarded PH specialists. “With fourteen treatments — which is as many or more…

On May 5, more than 80 organizations around the world will participate in activities designed to raise awareness of this often-misdiagnosed disease and to celebrate the lives of people living with what is called pulmonary hypertension (PH), or pulmonary arterial hypertension (PAH) — a condition of high blood pressure in…

Praxair, Inc., announced that it has received approval, through a subsidiary, for the sale of its Noxivent brand of inhaled nitric oxide in Canada. Noxivent is indicated for the treatment of newborns, including some born prematurely, suffering respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension (PH). PH in neonates can…

Researchers from Chungbuk National University, Korea, found that ranolazine (Ranexa), a drug used to treat coronary heart disease, effectively reduced the structural remodeling of the heart’s right ventricle in an animal model of pulmonary arterial hypertension (PAH). The results suggested that targeting right ventricle disease could delay PAH progression in people.

Blocking the enzyme sphingosine kinase 1 (SK1) reduced right ventricle enlargement in a mouse model of pulmonary arterial hypertension (PAH), while having no impact on blood vessel remodeling. The findings, published in the journal Cellular Signalling, highlighted disease mechanisms potentially crucial for future drug development. Scientists have…

Karos Pharmaceuticals announced that is advancing its small molecule drug candidate, KAR5585, in clinical testing as a treatment for pulmonary arterial hypertension (PAH) and other rare diseases characterized by fibrosis. A number of agents have recently been introduced as therapeutic drugs for PAH. Among them, KAR5585 is a first-in-class, selective inhibitor of an enzyme…

A study from Johns Hopkins School of Medicine showed that a cellular ion transporter might contribute to the increased expansion and migration of smooth muscle cells lining lung arteries in a model of pulmonary arterial hypertension (PAH). The findings provide new insights into disease mechanisms leading to blood vessel…

Balloon pulmonary angioplasty (BPA) appears to be of multiple benefit to patients with chronic thromboembolic pulmonary hypertension (CTEPH), both in terms of hemodynamics and in other systemic disorders like glycemic control and kidney disease, according to a study published in the journal Circulation, titled “Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients…

The Pulmonary Fibrosis Foundation (PFF) announced it has enrolled its first pulmonary fibrosis (PF) patient in the newly launched PFF Patient Registry, a collaborative effort involving patients, researchers, and healthcare providers that will gather data to advance PF research and improve patients’ quality of life. Enrollment takes place at participating PFF Care Center Network (CCN) sites across the…

A study recently published in the journal European Respiratory Review reported the case of a man with pulmonary hypertension resulting from silica exposure-induced sarcoidosis. The report urges clinicians to be aware of this rare cause of pulmonary hypertension, in which specific analyses are needed to confirm a diagnosis.